Compound Summary (CID 644241) Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment. [Wikipedia] From: DrugBank |
| | |
Identification Related Records Use and Manufacturing Pharmacology Biomedical Effects and Toxicity Safety and Handling Environmental Fate and Exposure Potential Exposure Standards and Regulations Literature Patents Biomolecular Interactions and Pathways Biological Test Results Classification Chemical and Physical Properties |